Lucentis Faces Academic Challenge
Funding for a multi-center trial to compare Genentech’s approved macular degeneration therapy with oncologic Avastin, used off-label to treat the disease, depends on NIH’s pending FY 2007 budget.
Funding for a multi-center trial to compare Genentech’s approved macular degeneration therapy with oncologic Avastin, used off-label to treat the disease, depends on NIH’s pending FY 2007 budget.